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Given the constant anguish of the popular press about 
the forthcoming onslaught of ‘andromeda strains’ which 
will bring an end to the golden age of antibiotics, the 
multi-resistant microbial pathogens refractory to 
forms of treatment, one might wonder what remains 
mysterious about antibiotic resistance? Pharmaceutical 
companies, the medical community, and countless 
researchers world-wide have been aware of the problem 
of antibiotic resistance for nearly fifty years and many 
papers have been written on the subject; surely every- 
thing is known about this phenomenon! Surprisingly 
(and perhaps sadly) the answer is no, the reason being 
that, while certain aspects of antibiotic resistance are 
well characterized, many essential facts concerning 
the genetic ecology of antibiotic resistance are poorly 
understood. Microbial antibiotic resistance (as we know 
it) is the result of exorbitant antibiotic usage over 
the past half-century. It is clear that much of this use 
is, at best, inappropriate. Only half of the world 
production of antibiotics goes into human therapy, 
the remainder is employed in agriculture, aquaculture, 
animal husbandry, and the like. However, it is too 
late to lay blame - we cannot turn back the clock. 
Responsibility for loss of clinical effectiveness due to 
the development of antibiotic resistance must be borne 
by all. 
What more do we need to know about the subject? 
Following the introduction of antibiotics into thera- 
peutic use, microbes developed resistance very rapidly, 
and although chromosomal mutations are likely to 
have played an important role in the initial steps, the 
major route by which bacteria became resistant was 
gene acquisition, principally from antibiotic-producing 
organisms in the environment, but most probably from 
other microbial sources as well. All well and good, but 
what  microbes first inherited the resistance genes? 
The original beneficiaries of the natural exchange of 
resistance genes - Grani-positive, Gram-negative, culti- 
vatable, non-cultivatable, pathogen or non-pathogen - 
cannot be identified. The initial events cannot be 
re-created. Plausible genetic mechanisms for the ‘pick- 
up’ of resistance genes have been identified for some 
microbial species, but not all. The available evidence 
suggests that the pattern of resistance gene flow was 
from Gram-positive to Gram-negative bacteria, but the 
mechanisms of prior acquisition by the Gram-positives 
is unknown. And what of dissemination? Did this 
take place by one or several different mechanisms, and 
pathways, before reaching the current Gram-negative 
pathogens? How many inter-generic and inter-specific 
transfers through how many different hosts were 
required? There are great gaps in the understanding 
of these processes. What promotes dissemination? 
What are the routes of dissemination of resistance genes 
from the microbial populations of animals to humans, 
or humans to animals or fish? Unfortunately, the 
opportunity to carry out definitive studies of the 
origins and development of antibiotic resistance has 
been missed, since most examination of the origins and 
dissemination of antibiotic resistance must be retro- 
spective, long after the event in microbial terms, and 
the exact scenarios are difficult to reproduce. 
Were this information available we would be in a 
better position to evaluate the implications of the use 
of antibiotics as animal growth promotants or fish food 
and the contribution of non-human use of antibiotics 
to the overall problem of development and spread of 
resistance. In addition, do we know the red economic 
benefits of antibiotic use in agriculture and aqua- 
culture? Are existing practices truly effective and have 
alternatives been investigated? Given that the whole 
process is so multi-functional, from the point of view 
of genetics and biochemistry as well as in terms of the 
economics of animal husbandry, etc., is there time to 
re-evaluate every aspect of antibiotic usage before it 
creates a health, environmental, and economic disaster? 
Realistically, all antibiotic therapy must be con- 
sidered in the context of the inevitable - resistance to 
any drug will develop sooner or later. Can one hope 
for the introduction of practices that make it later? 
How can we delay this inevitability without a better 
understanding of the biological processes involved? 
Filling in the gaps in our knowledge of how microbes 
become resistant to antibiotics might give us better 
ideas of how to combat the overall problem. There 
is a need to expand our understanding of the basic 
microbial genetic ecology involved. This requires much 
more fundamental research, but who will (should) 
pay for this? Everyone! Ail users and abusers and 
their regulatory agencies (pharmaceutical companies, 
agricultural feed companies, appropriate government 
departments, and the public) have a vested interest in 
maintaining the efficacy of antibiotics. 
New antibiotics are coming along and the pharma- 
ceutical industry needs to recoup its extensive invest- 
ment in research and development. However, one 
would hope that introduction of the next major 
antibiotic class (soon and several, we hope) will be 
governed by increasing awareness and comprehension 
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of the negative aspects of antibiotic use. The ‘new’ 
antibiotics must be dispensed prudently for human 
therapy, regulated by clinicians, pharmacists, etc., with 
the knowledge that departure from such regimes will 
convert valuable drugs into a plethora of ‘me-toos’ 
in a constant chemical battle to keep ahead of the 
microbes. 
Antibiotic discovery and subsequent use is chang- 
ing. The enormous efforts in genomic analysis of 
bacterial pathogens will undoubtedly identifj many 
new drug targets; in a few years time the nucleotide 
sequence of the genomes of most pathogens will be 
known. The most obvious result of this effort will 
be pathogen-specific inhibitors. The controlled use of 
narrow-spectrum (or niche-specific) antibiotics in the 
place of random use of broad-spectrum agents is surely 
one way to reduce the global problem of antibiotic 
resistance. For this to be implemented, accurate clinical 
and microbiological diagnosis will be a required adjunct 
to antibiotic prescription and is likely to be expensive. 
Will this paradigm change be accepted by pharma- 
ceutical marketing divisions, the medical profession, 
HMOs? Can we count on a corresponding develop- 
ment of rapid, automated diagnostic technology needed 
to make the best use of drugs active against specific 
bacterial species? Everything done up to now has been 
‘damage control’ - a knee jerk reaction to something 
that has happened. Is it not time to be prospective 
instead of retrospective? 
Only when the mysteries of the evolution of 
resistance, the efficacy of present practices, and the 
economics of drug discovery and use are resolved will 
it be possible to envisage the future of antibiotics in the 
treatment of infectious disease. Ironically, a similar 
viewpoint was stated 40 years ago by Sir Charles 
Harington in his introductory remarks to a CIBA 
Foundation Symposium on Drug Resistance in Micro- 
Organisms: 
We cannot be sure that the searchers for new drugs and 
antibiotics will always win the race. However hard and 
successftrlly we may work in the search for new drugs we shall 
therefore continue to labour under discouragement so long as 
we arefaced with the bugbear o f  drug resistance. The problem 
is one o f  microbial biochemistry, physiology and genetics, and 
can only be solved by work in thesejelds. Until we understand 
the problem we shall have no hope ofovercoming it, and until 
we overcome it we shall have no real sense ofsecurity in our 
chemotherapy. The subject . . . is not only o f  the greatest 
scientific interest and importance; it has also a background .f 
practical medical urgency. 
March 1957 
It would seem that no one was really listening! 
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